A bright future for LAG-3? Top analysts see an arms race in the making, but drugmakers need a biology breakthrough
With the success of PD-1 as a target for a growing suite of “miracle” I-O drugs, the race is on to find another inhibitory immune checkpoint to keep growing the field. The competitors in the clinic are numerous — TIGIT, TIM-3, Galectin-9, for example — but a team of top analysts is calling out a particularly bright future for one target, assuming drugmakers can nail the biology.
The checkpoint inhibitor LAG-3 could see an explosion in numerous cancer types outside of melanoma in the coming years, but a mix of little-understood biology and widely disparate late-stage clinical results is putting a damper on the field’s early chances, SVB Leerink analysts wrote in a note to clients Thursday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
